← Back to patent-cliff list
HS-10501
Tier C — Watch / tradeHS-10501
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GLP1R
Indications (approved)：Type 2 diabetes, Overweight, Obesity
Regional status
US
-
EU
-
China
Phase II
2025-05-06
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HS-10501?
Approved indications include: Type 2 diabetes, Overweight, Obesity.
When does the HS-10501 patent expire?
No public expiry year is available for HS-10501 yet; this page updates once verified.
How do I get a quote for HS-10501 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30